Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 clinical trials at UCSF
1 in progress, 0 open to new patients
Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Sorry, not yet accepting patients
This phase I trial studies the side effects and best dose of talimogene laherparepvec and to see how well it works in treating patients with non-muscle invasive bladder transitional cell carcinoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them.
San Francisco, California